- Location
hepatocellular carcinoma
"-
Monitoring Inactive Chronic Hepatitis B (Hbv) Carriers Is a Cost-Effective Strategy
Jan 16, 2014A novel study determined that monitoring inactive chronic hepatitis B (HBV) carriers is a cost-effective strategy for China. However, results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, ...
-
People with Type 2 Diabetes Might Be at Somewhat Higher Risk of Developing Liver Cancer
Dec 26, 2013People with type 2 diabetes might be at somewhat higher risk of developing liver cancer, according to a large, long-term study. The research suggests that those with type 2 diabetes have about two to three times greater risk of developing ...
Tags: type 2 diabetes, liver cancer, hepatocellular carcinoma
-
FDA Has Approved Sovaldi 400mg Tablets
Dec 10, 2013Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved Sovaldi (sofosbuvir) 400mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (CHC) infection ...
Tags: Gilead Sciences, Chronic Hepatitis
-
Bayer and Onyx Have Announced FDA Priority Review Designation
Aug 29, 2013Bayer HealthCare and Onyx Pharmaceuticals have announced FDA priority review designation for Nexavar (sorafenib) supplemental new drug application for the treatment of radioactive iodine-refractory differentiated thyroid cancer. Nexavar ...
Tags: New Drug Application, FDA
-
Alnylam Pharmaceuticals and Ascletis Pharmaceuticals Have Entered Into a Partnership
Nov 29, 2012Alnylam Pharmaceuticals and Ascletis Pharmaceuticals have entered into a partnership to develop a systemically delivered RNAi therapeutic, ALN-VSP, for the treatment of liver cancers including hepatocellular carcinoma (HCC). Under the ...
Tags: Alnylam Pharmaceuticals, Ascletis Pharmaceuticals, HCC, ALN-VSP
-
Jennerex Starts Phase 2 Hcc Trial of Jx-594
Nov 27, 2012Jennerex has treated the first patient in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma(HCC)who have not received treatment with sorafeni. The ...
Tags: hepatocellular carcinoma, JX-594, intravenous treatment, Jennerex
-
ArQule and Daiichi Sankyo Have Signed a Special Protocol Assessment Agreement
Oct 17, 2012ArQule and Daiichi Sankyo have signed a special protocol assessment (SPA) agreement with the FDA for Phase 3 trial of Tivantinib in hepatocellular carcinoma (HCC). The SPA process enables FDA to offer official evaluation and written ...
Tags: ArQule, Daiichi Sankyo, SPA, FDA
